We are live on ! Find out more
BOLT icon

Bolt Biotherapeutics
BOLT

62 hedge funds and large institutions have $165M invested in Bolt Biotherapeutics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

0.27% less ownership

Funds ownership: 4.77% → 4.51% (-0.27%)

13% less funds holding

Funds holding: 71 → 62 (-9)

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

63% less capital invested

Capital invested by funds: $449M → $165M (-$284M)

75% less funds holding in top 10

Funds holding in top 10: 4 → 1 (-3)

Holders
62
Holders Change
-9
Holders Change %
-12.68%
% of All Funds
0.95%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
11
Increased
25
Reduced
12
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$8.69M
2
SCM
Suvretta Capital Management
New York
+$8.59M
3
Morgan Stanley
Morgan Stanley
New York
+$2.55M
4
BlackRock
BlackRock
New York
+$1.84M
5
Holocene Advisors
Holocene Advisors
New York
+$1M

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$20.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.5M
3
SC
Samlyn Capital
New York
-$9.38M
4
ABG
Ally Bridge Group
New York
-$3.25M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$2.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$22.1M – – –
VC
2
Vivo Capital
California
$19M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$13.8M -$639K -3,368 -2%
SI
4
Sofinnova Investments
California
$13.5M – – –
RCM
5
RA Capital Management
Massachusetts
$11.7M – – –
SCM
6
Suvretta Capital Management
New York
$10.9M +$8.59M +45,238 +68%
PBPIA
7
Pivotal bioVenture Partners Investment Advisor
California
$9.27M – – –
BlackRock
8
BlackRock
New York
$8.08M +$1.84M +9,709 +13%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$7.33M -$12.5M -65,971 -47%
EAM
10
Eventide Asset Management
Massachusetts
$7.1M +$8.69M +45,775 +171%
Holocene Advisors
11
Holocene Advisors
New York
$6.21M +$1M +5,289 +9%
NFGH
12
Nan Fung Group Holdings
Hong Kong
$5.72M – – –
Vanguard Group
13
Vanguard Group
Pennsylvania
$4.89M +$46.3K +244 +0.5%
SB
14
Samsara BioCapital
California
$3.61M – – –
BOTOTLSJU
15
Board of Trustees of The Leland Stanford Junior University
California
$3.53M – – –
Goldman Sachs
16
Goldman Sachs
New York
$2.35M +$352K +1,857 +8%
Morgan Stanley
17
Morgan Stanley
New York
$2.21M +$2.55M +13,441 +147%
WP
18
Woodline Partners
California
$1.98M +$85.6K +451 +2%
Geode Capital Management
19
Geode Capital Management
Massachusetts
$1.92M +$446K +2,351 +14%
State Street
20
State Street
Massachusetts
$1.53M +$309K +1,627 +12%
Northern Trust
21
Northern Trust
Illinois
$955K +$77.1K +406 +4%
HCM
22
Hawkeye Capital Management
Florida
$823K +$1.59M +8,400 New
EC
23
EcoR1 Capital
California
$735K – – –
RI
24
RTW Investments
New York
$619K – – –
DCM
25
DAFNA Capital Management
California
$490K – – –
1
2 3 4

BOLT Hedge Fund Activity: Q4 2021 in Review

62 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2021, worth a combined $165M — down 63% from $449M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of BOLT and 11 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 25 added.

The largest buyer was Eventide Asset Management, adding an estimated $8.69M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $20.9M sold.

  • 62 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2021, down from 71 in Q3 2021.
  • Funds reported $165M of Bolt Biotherapeutics stock for Q4 2021, down 63% quarter-over-quarter.
  • 11 funds opened new Bolt Biotherapeutics positions in Q4 2021 and 20 closed out, a net change of -9 holders.
  • The largest Bolt Biotherapeutics buyer in Q4 2021 was Eventide Asset Management, an estimated $8.69M added.
  • The largest Bolt Biotherapeutics seller in Q4 2021 was Rock Springs Capital Management, an estimated $20.9M sold.

Based on aggregated 13F filings for Q4 2021.